Bio-Techne Corporation’s stock price plunges to $47.86, recording a 7.27% drop – What’s next?

Bio-Techne Corporation (TECH)

47.86 USD -3.75 (-7.27%) Volume: 2.85M

Bio-Techne Corporation’s stock price dips to 47.86 USD, marking a significant trading session drop of 7.27% and a year-to-date decrease of 33.56%, amidst a high trading volume of 2.85M shares, spotlighting the company’s challenging market performance in the biotechnology sector.

Latest developments on Bio-Techne Corporation

Today, Bio-Techne Corp. stock experienced underperformance compared to its competitors in the biotech industry. Despite this, investors are still viewing Bio-Techne Corporation (TECH) as a compelling addition to their portfolios. Recently, Bio-Techne showcased their next-generation solutions for gene and cell therapy at the American Society of Gene & Cell Therapy 2025 conference, highlighting their innovative approach to the industry. Additionally, the company presented at the BofA Securities 2025 Healthcare Conference, discussing their strategic growth plans amidst current challenges. Overall, Bio-Techne’s stock movements today reflect both industry competition and investor interest in their cutting-edge technologies.

Bio-Techne Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely following Bio Techne Corp‘s latest developments. In a recent report titled “Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!”, they highlighted the company’s second quarter results for fiscal year 2025. Despite facing some challenges, Bio-Techne Corporation saw a 9% year-over-year increase in revenue, reaching $297 million in total sales. The growth was driven by strong performance in the biopharma end markets, particularly in large pharmaceutical orders for GMP reagents and protein analytical implementations, as well as advancements in their ExosomeDx and spatial biology divisions.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio Techne Corp has a neutral outlook across all factors including value, dividend, growth, resilience, and momentum. This suggests that the company is performing steadily in these areas without any significant strengths or weaknesses. Bio Techne Corp develops, manufactures, and sells biotechnology products and clinical diagnostic controls, specializing in proteins, cytokines, growth factors, immunoassays, and small molecules.

While Bio Techne Corp may not stand out in any particular aspect according to the Smartkarma Smart Scores, its overall outlook remains stable. With a focus on biotechnology products and clinical diagnostic controls, the company continues to operate in a competitive industry. Investors may consider the neutral scores across various factors when evaluating the long-term potential of Bio Techne Corp in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma